

# **ADAP Medical Advisory Committee**

## **October 16, 2024 Gathering Notes**

### **1) Welcome and Rollcall**

#### I. Welcome:

Gathering opened by James Vo, ADAP Formulary Specialist

#### MAC Members in Attendance

Lucas Hill, Cliff Okada, Joanna Eveland, Danny Toub, David Grelotti

#### CDPH/Office of AIDS staff in Attendance

Philip Peters, James Vo, Alej Contreras, Linda Lewis

#### MAC Members not in Attendance

David Lewis, Stephen O'Brien, Michelle Sherman, Laveeza Bhatti, Arlet Arratoonian

#### Prime Representatives in Attendance

Carrie Holden

### **2) ADAP / MAC Updates**

#### I. Medications added to the ADAP formulary and updates:

- Medications added on September 24, 2024: amlodipine/benazepril, Lotrel, amlodipine/olmesartan, Azor, amlodipine/valsartan, Exforge, amlodipine/valsartan/hydrochlorothiazide (HCTZ), Exforge-HCT, atenolol/chlorthalidone, Tenoretic, benazepril/HCTZ, Lotensin-HCT, enalapril/HCTZ, Vaseretic, metoprolol/HCTZ, Lopressor-HCT, olmesartan/HCTZ, Benicar-HCT, valsartan/HCTZ, Diovan-HCT.
- The California Planning Group will be meeting in person on Nov. 20-22 in Riverside, CA where community stake holders for the Office of AIDS to provide advice for general prevention programming. Dr. Peters and Alej Contreras will make an effort to recruit community members to the ADAP MAC.
- Medications that are in the final stages to being added to the ADAP formulary: Bedaquiline, Pretomanid, Paxlovid, Opill, Clomid, Human chorionic gonadotropin (Novarel, Pregnyl).

#### II. Medications removed from the ADAP formulary:

- None

#### III. Update on the medications discussed during the July 2024 MAC Gathering:

- Weight loss medications: Tirzepatide and Semaglutide undergoing cost analyses process

### **3) Medication Discussion**

#### I. Dr. Grelotti ADHD medications to add to the ADAP formulary:

- a. Adderall-XR

- b. Mydayis
- c. Vyvanse

II. Sexual health medications:

- a. Vaginal Estrogen

**4) PrEP-AP Formulary**

- I. Hepatitis C medications ongoing cost analysis.
- II. Gender Affirming Medications: Conjugated estrogen/bazedoxifene, estradiol, leuprolide, raloxifene, spironolactone, testosterone will be added by end of October 2024.
- III. Lenacapavir to be approved by United States Food and Drug Administration as soon as July 2025.
- IV. Gilead ending patient assistance program for Truvada on December 31, 2024.

**5) Opportunistic Infection Treatments**

- I. No public comment

**6) Prime Presentation**

- I. Dr. Peters presented on:

- ADAP Open Formulary

- II. Public Comment:

- No public comment

**7) Close of Meeting**

- I. The next ADAP MAC gathering is scheduled for January 15, 2025, from 7:30 a.m. to 9:00 a.m.

**8) Action Items**

Action Items	Owners
Vaginal Estrogen Review	Dr. Peters/James
Insomnia Medications	Carrie Holden